NCT06132711View on ClinicalTrials.gov

Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
Multiple Myeloma
Interventions
OTHER

APRIL-BAFF-Bicephali CAR-T cells

Peripheral blood mononuclear cells were collected and subjected to CD3+T cells were enriched, transfected with APRIL-BAFF-Bicephali lentiviral vector, expanded by in vitro culture, and pretreated with clear lymphocytes using the FC protocol before infusion of APRIL-BAFF-Bicephali CAR-T cells.

Trial Locations (1)

221000

RECRUITING

Kailin Xu, Xuzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Xuzhou Medical University

OTHER